TrialReader


CGM Use in Children With Type 2 Diabetes

NCT04721158 — Not applicable, Completed, 41 participants, Johns Hopkins University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

IMPlementation of Continuous Glucose Monitoring in Children With Type 2 Diabetes

RegistryNCT04721158, acronym IMPaCT2
StatusCompleted
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, supportive care
Enrollment41 (Actual)
SponsorJohns Hopkins University (Other)
ConditionsType 2 Diabetes, Hyperglycemia Due to Type 2 Diabetes Mellitus
InterventionsContinuous glucose monitor (Device)
Datesstart 2021-01-17, primary completion 2022-07-28, completion 2022-07-28, first posted 2021-01-22, last updated 2023-09-15
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Type 2 Diabetes All trials for Hyperglycemia Due to Type 2 Diabetes Mellitus All trials of Continuous glucose monitor

-Summary

The purpose of this prospective study is to determine if trial use of a Dexcom G6 CGM system for a 10 day wear period in pediatric Type 2 diabetes patients improves short term time in range glucose control and 3-6 month glycemic control.

Expand all sections  ·  Collapse all

+Detailed description

The purpose of this prospective study is to determine if trial use of a Dexcom G6 CGM system for 10 days has an impact on short and long term glycemic control and behavior in youth onset Type 2 diabetes.

+Arms and interventions

ArmTypeInterventionsDescription
CGM ArmOtherDevice: Continuous glucose monitorChildren with type 2 diabetes will wear a continuous glucose monitor for 10 days.
  • Continuous glucose monitor (Device), also known as Dexcom G6 CGM: Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.

+Outcome measures

Primary outcomes

  • Percentage of Time in Range Glucose Control [5 days, 10 days]: The percentage of total time that the patient uses the continuous glucose monitor (CGM) where the blood glucose falls between 70 and 180 mg/dL
  • Hemoglobin A1c [Baseline, 3 - 6 months]: HbA1c at baseline and 3-6 month follow-up.
  • More Frequent Insulin Administration [10 days from CGM placement]: Response to "Did you take your insulin more often than before?"
  • More Frequent Glycemic Control Monitoring [10 days]: Response to "Do you look at or check your blood sugar more often than before?"

+Eligibility

Sex: All, ages: 5 Years to 21 Years

Inclusion Criteria:

* Type 2 diabetes, diabetes duration >3 months

Exclusion Criteria:

* Prior use of CGM

+Posted results

Participant flow

MilestoneCGM Sample Given
Started41
Completed36
Not completed5

Outcome results

  • Percentage of Time in Range Glucose Control (Primary), Mean, percentage of time in target range: CGM Sample Given 49.2 +/- 38
  • Hemoglobin A1c (Primary), Mean, percentage of glycosylated hemoglobin A1: CGM Sample Given 10.2 +/- 2.8
  • More Frequent Insulin Administration (Primary), Count of participants, Participants: CGM Arm 14
  • More Frequent Glycemic Control Monitoring (Primary), Count of participants, Participants: CGM Arm 23

Adverse events

Time frame: 6 months

ArmDeathsSerious adverse eventsOther adverse events
CGM Arm0/41 (0.0%)2/41 (4.9%)0/41 (0.0%)

Serious adverse events by term

TermOrgan systemCGM Arm
DKA admissionEndocrine disorders2/41

Limitations and caveats: The limitations of this study include the small study size with a limited number of participants completing both 10-day trial period and 3/6-month follow up visits. There were a large number of patients who had device connectivity and adhesive issues. Many participants were lost to follow up.

+Locations (1)

FacilityCityCountryStatus
Johns Hopkins Pediatric Diabetes CenterBaltimore, MarylandUnited States

+Publications

  • Results publication: Phu A, Lin T, Manfredo JA, Brown EA, Wolf RM. Similar Perceptions on Continuous Glucose Monitor Use amongst Youth with Type 1 and Type 2 Diabetes. Pediatr Diabetes. 2023 Jun 19;2023:1979635. doi: 10.1155/2023/1979635. eCollection 2023. PMID 40303266

+Study documents

+Investigators

My Notes